"I am very pleased with the use of the Proteus device in my patients. It is simple to use and cost effective and I can now be assured that my patients will have a significant reduction in risk from the PTA procedure," said Dr. Subhash Banerjee, Chief, Division of Cardiology, from VA North Texas Health Care System, Dallas, TX.
"Being part of the company's Scientific Advisory Board from its early days, I am very excited that Proteus has received FDA clearance for use in the lower limbs. Proteus and Embolic Capture Angioplasty will reduce the risk of complications for our patients and in the future could become the gold standard for angioplasty procedures," said Dr. John Laird, Medical Director, UC Davis Vascular Center, Sacramento, CA.
Investors in Angioslide include Ofer Hi-Tech, Viola Group, Itochu Corporation and Agate Medical Investments.
United States operations are led by Tom Doorley, Senior VP of Sales, and John Schorgl, both former executives with Schneider/Pfizer.
Angioslide is a privately held company with headquarters in Herzliya, Israel. Its U.S. distribution headquarters is located in Minneapolis, MN. Its European distribution headquarters is located in Karlsruhe, Germany.
The Proteus product line, Embolic Capture Angioplasty and ECA are trademarks of Angioslide Ltd.
Note: This press release contains forward-looking statements that are based upon management's present expectations and are essentially uncertain. Actual results and timing of events could differ materially from current expectations and from any forward-looking statements.
The company's first product is Proteus which is indicated for use in the
United States for usage in the lower limbs. Angioslide c
|SOURCE Angioslide Ltd.|
Copyright©2010 PR Newswire.
All rights reserved